Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Infinitech's Perfluoron cleared:

This article was originally published in Clinica

Executive Summary

Infinitech's perfluorocarbon liquid, Perfluoron, has received US FDA approval less than one year after the St Louis-based company filed for pre-market approval. Perfluoron was granted expedited review status by the FDA and the agency's Ophthalmic Devices Panel recommended approval late last year. The liquid offers an alternative to silicone oil or gases for injecting into the eye during retinal reattachment surgery to flatten the damaged retinal membrane. The company estimates a $15-20 million US market annually for its product, with a similar international market.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT087726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel